Dose Optimization of Rivaroxaban in Elderly Chinese Patients with Non-Valvular Atrial Fibrillation: Analysis of Populations Pharmacokinetics and Exposure-Response Relationships
For elderly Chinese NVAF patients, a reduced-dose rivaroxaban regimen, specifically 10 mg once daily with amiodarone, is recommended for all patients regardless of renal function, whereas 15 mg once daily is a more optimal option for those not taking amiodarone. Based on the risk-benefit assessment, maintaining AUC<sub>24,ss</sub> above 2840 ng·h/mL does not yield additional clinical benefit.
Authors
- Wei Cai (ORCID: https://orcid.org/0000-0001-9324-5987)
- Bijue Liu (ORCID: https://orcid.org/0009-0003-1171-8587)
- Ya Su (ORCID: https://orcid.org/0000-0002-1633-3331)
- T. Li (ORCID: https://orcid.org/0000-0001-5208-6481)
- Xin Liu (ORCID: https://orcid.org/0009-0009-5595-3195)
- Chun Liu (ORCID: https://orcid.org/0000-0002-2479-0866)
- Jun Zhang (ORCID: https://orcid.org/0000-0002-6523-7573)
- Chao Yu
- Lian Tang (ORCID: https://orcid.org/0000-0002-8059-8166)
- Yanxia Yu (ORCID: https://orcid.org/0009-0000-9752-2806)
- Lisheng Jiang (ORCID: https://orcid.org/0000-0003-2966-2828)
Institutions
- Nantong University (CN)
- Fudan University (CN)
- Ruijin Hospital (CN)
- Suzhou Municipal Hospital (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
- Wuxi People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/dddt.s563521
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jiangsu Pharmaceutical Association